source
- CRISPR Therapeutics to test highest dose of lipid‑lowering gene editing therapy after mixed durability dataCRISPR Therapeutics presented early‑stage data at the European Society of Cardiology meeting showing that its lipid‑lowering gene editing candidate produced mixed durability results a year after pa…
- BioNTech-Genentech halts colorectal cancer vaccine trial after higher death rate in vaccine armBioNTech and Genentech stopped a phase 2 trial of their personalized mRNA vaccine BNT122 in patients with stage 2 or 3 colorectal cancer after an independent data safety monitoring board found more…